Ketamine for Depression: An MRI Study
Brief Summary
Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has been shown to last for up to one month. MRI technology will be used before and after ketamine for patients with depression to examine the extent to which certain brain areas predict ketamine's antidepressant effects.
Condition or Disease
- Depression
- Anxious Depression
- Major Depressive Disorder
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Completed |
| Study results: | Has Results |
| Age: | 18 Years to 64 Years (Adult) |
| Enrollment: | 25 () |
| Funded by: | Other|NIH |
Masking |
|
Clinical Trial Dates
| Start date: | Mar 16, 2022 | |
|---|---|---|
| Primary Completion: | Dec 29, 2017 | |
| Completion Date: | Dec 29, 2017 | |
| Study First Posted: | Sep 09, 2015 | |
| Results First Posted: | Apr 04, 2019 | |
| Last Updated: | Apr 16, 2019 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Ketamine's antidepressant effects were measured with Hamilton Depression Rating Scale (HDRS). MRI data will also be analyzed to examine the extent to which certain brain areas predict ketamine's antidepressant effects.
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 64 |
More Details
| NCT Number: | NCT02544607 |
|---|---|
| Other IDs: | 2015P001912|24032 |
| Study URL: | https://ClinicalTrials.gov/show/NCT02544607 |
Last updated: Jun 17, 2022